Ekonomi Bölümü Koleksiyonu

Permanent URI for this collectionhttps://hdl.handle.net/20.500.11779/1936

Browse

Filters

2019 - 201912020 - 20252

Settings

Publication Index: search.filters.publicationIndex.ScopusScopus Q: search.filters.scopusQuartile.N/A

Search Results

Now showing 1 - 3 of 3
  • Book Part
    Precarious Work and Individual Deprivation During the Post-COVID Era: Lessons From Turkey
    (Edward Elgar Publishing Ltd., 2025-05-13) Kinikoğlu, C.N.; Karahasan, B.C.
  • Book Part
    Citation - Scopus: 2
    New Money: Central Bank Digital Currencies
    (Peter Lang AG, 2019) Karamollaoğlu, Nazlı; Tuncay, Berna
    Payment systems have been evolving along with technological advancements in the last couple decades. The introduction of different forms of electronic banking, the advance of Internet banking services, and advances in mobile phone and mobile payment technology have reduced the use of physical currency. Additionally, the first mover cryptocurrencies, bitcoin and its various alternatives (e.g., Ether, Litecoin), have been expanding their footprints, despite the volatility of their prices and the issues with their capability. These developments pose both opportunities and threats for Central Banks, particularly in the formulation of monetary policy and regulation of payment systems. Increased adoption of cryptocurrencies for payment transactions could undermine central banks' monetary policy missions as their policy power over the money in circulation would weaken. Weakened monetary policy control on the central bank side would risk financial stability. On the other hand, cryptocurrencies may also have positive impacts on the economy through various channels such as cost and time driven payment market efficiencies, financial inclusion, cashless society, and smaller informal sector. A central bank digital currency (CBDC) may have various characteristics related to its store of value, availability, settlement time, wallet and transaction limits, extent of use, being interest bearing or not and level of anonymity. While each characteristic has its own pros and cons, decisions on the CBDC characteristics need to be made by taking into account the country's circumstances, priorities, and ultimate policy objectives. © Peter Lang GmbH Internationaler Verlag der Wissenschaften Berlin 2019. All rights reserved.
  • Article
    Citation - WoS: 27
    Citation - Scopus: 30
    Prevalence of Mastocytosis and Hymenoptera Venom Allergy in the United States
    (Mosby-Elsevier, 2021-11-01) Volertas, Sofija; Akın, Cem; Khokhar, Dilawar; Schuler, Charles F; Chen, Lu; Yüce, Huseyin; Montejo, Jenny M; Başer, Onur
    Background : Mastocytosis is a risk factor for hymenoptera venom anaphylaxis (HVA). Current guidelines recommend measuring tryptase in HVA patients and that those with mastocytosis pursue lifelong venom immunotherapy (VIT). Available data on HVA and mastocytosis largely derives from European single-center studies and the prevalence of HVA with and without mastocytosis in the United States (US) is unknown.Objective : We sought to determine the prevalence of HVA and mastocytosis in the US using an insurance claims database and evaluate the impact of mastocytosis on VIT in HVA patients in a US cohort. Methods :The IBM Watson Database, consisting of insurance claims from approximately 27 million US patients in 2018, was queried to identify patients with HVA and/or mastocytosis. Further, a retrospective study of 161 patients undergoing VIT between 2015 – 2018 at the University of Michigan (U-M) was conducted. Results :In the IBM Watson Database, the prevalence of HVA was 167 per 100,000 (0.167%) and the prevalence of mastocytosis 10 per 100,000 (0.010%) overall and 97 per 100,000 (0.097%) among those with HVA. Mastocytosis showed a 9.7-fold increase among HVA patients versus the general population. In the U-M cohort, 2.6% of VIT patients had mastocytosis. Tryptase level did not correlate with venom reaction severity but was higher in patients with systemic VIT reactions. Conclusions :We observed a lower US HVA prevalence than previously reported. Mastocytosis was more common in US HVA patients, though at lower rates than previously reported. In VIT patients there was no correlation between tryptase level and reaction severity. Key words :Tryptasevenom allergyvenom immunotherapyanaphylaxismastocytosismast cell activation syndromemast cell disease Abbreviations Hymenoptera venom allergyHVAUnited StatesUSVenom immunotherapyVITMast Cell DiseaseMCDAmerican Academy of Allergy, Asthma, and Immunology